Suppr超能文献

首次喘息的婴儿使用单剂量与多剂量地塞米松的比较。

A single versus multiple doses of dexamethasone in infants wheezing for the first time.

作者信息

Schuh Suzanne, Coates Allan L, Dick Paul, Stephens Derek, Lalani Amina, Nicota Erika, Mokanski Matthew, Khaikin Svetlana, Allen Upton

机构信息

Pediatric Emergency Medicine, The Hospital for Sick Children, Toronto, ON, Canada.

出版信息

Pediatr Pulmonol. 2008 Sep;43(9):844-50. doi: 10.1002/ppul.20845.

Abstract

RATIONALE

Corticosteroid therapy is not routinely recommended in true bronchiolitis. However, since bronchiolitis and the first asthma attack are impossible to distinguish, some infants with the first wheezing episode receive corticosteroids. Optimal duration of corticosteroid therapy in this scenario is unknown. This study compared efficacy of multiple administrations and a single dose of dexamethasone in bronchiolitis.

METHODS

In this randomized double blind trial, previously healthy outpatients 2-23 months of age with bronchiolitis and Respiratory Disease Assessment Instrument (RDAI) score 6 or more received 1 mg/kg of oral dexamethasone in the Emergency Department. Prior to discharge at 4 hr they were randomized to either 4 daily doses of dexamethasone 0.15 mg/kg or placebo equivalent. Primary outcome was the proportion of subsequent hospitalizations or prescribed trials of bronchodilator/corticosteroid therapy for dyspnea by day 6 in the groups. Secondary outcomes were changes in the RDAI to day 6, and proportions with unscheduled visits by days 6 and 28.

RESULTS

The rate of primary outcome in the single dose group (SDG, N = 64) was 9/64 or 14.1% versus 7/61 or 11.5% in the multiple dose group (MDG, N = 61) [95% CI 0.09; 0.14]. Twelve (18.8%) children in the SDG had unscheduled medical visits by day 6 versus 11 (18.0%) children in the MDG [95% CI 0.13; 0.14]. On day 6 the RDAI decreased from 9.5 +/- 2.1 to 2.1 +/- 2.4 in the SDG and from 9.8 +/- 2.2 to 1.6 +/- 2.3 in the MDG [95% CI 0.36; 2.06]. Between days 7-28, 24/64 (37.5%) SDG infants returned for care versus 20/61 (32.8%) of the MDG [95% CI 0.12; 0.21].

CONCLUSIONS

Our study suggests that, in outpatients with bronchiolitis who receive dexamethasone, continuation of this agent beyond the initial dose does not provide significant benefit.

摘要

理论依据

在真正的细支气管炎中,通常不推荐使用皮质类固醇疗法。然而,由于细支气管炎和首次哮喘发作难以区分,一些首次出现喘息发作的婴儿会接受皮质类固醇治疗。在这种情况下,皮质类固醇治疗的最佳疗程尚不清楚。本研究比较了多次给药和单剂量地塞米松治疗细支气管炎的疗效。

方法

在这项随机双盲试验中,年龄在2至23个月、患有细支气管炎且呼吸系统疾病评估工具(RDAI)评分达到6分或更高的健康门诊患者,在急诊科接受1mg/kg的口服地塞米松治疗。在4小时出院前,他们被随机分为两组,一组每天服用4次0.15mg/kg的地塞米松,另一组服用等效安慰剂。主要结局是两组中到第6天时因呼吸困难而再次住院或接受支气管扩张剂/皮质类固醇治疗的比例。次要结局是到第6天时RDAI的变化,以及到第6天和第28天进行非计划就诊的比例。

结果

单剂量组(SDG,N = 64)的主要结局发生率为9/64或14.1%,而多剂量组(MDG,N = 61)为7/61或11.5% [95%可信区间0.09;0.14]。单剂量组中有12名(18.8%)儿童在第6天进行了非计划就诊,多剂量组中有11名(18.0%)儿童 [95%可信区间0.13;0.14]。在第6天,单剂量组的RDAI从9.5±2.1降至2.1±2.4,多剂量组从9.8±2.2降至1.6±2.3 [95%可信区间0.36;2.06]。在第7至28天期间,单剂量组中有24/64(37.5%)的婴儿回来接受治疗,多剂量组中有20/61(32.8%) [95%可信区间0.12;0.21]。

结论

我们的研究表明,在接受地塞米松治疗的细支气管炎门诊患者中,初始剂量之后继续使用该药并无显著益处。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验